June 10, 2008 - The use of ultrasound contrast agents during stress echocardiograms is safe, according to results presented at the 19th Annual Scientific Sessions of the American Society of Echocardiography.

These findings are significant after the FDA mandated a black box warning on labels of contrast agents used for cardiovascular ultrasound.

The research, conducted at the Methodist DeBakey Heart and Vascular Center in Houston, TX, showed the risk of major adverse effects is no different in patients that received contrast during their stress echocardiogram than in those who did not receive contrast, according to research findings. This held true even though contrast was more often used in patients with a higher cardiac risk profile.

The study examined 3,121 consecutive patients who underwent stress echocardiograms from 2002 through 2007 at The Methodist Hospital.

Researchers evaluated demographics, contrast use, hemodynamics, ECG and wall motion changes, symptoms and arrhythmias. Contrast was administered in 1,879 of 3,121 patients (60 percent). None of the patients receiving an ultrasound contrast agent experienced sustained ventricular tachycardia, ventricular fibrillation, cardiac arrest or death.

"Contrast-enhanced stress echocardiography is a safe option to attain important diagnostic information for patients who need more testing than cardiac ultrasound alone," said Kamran Shaikh, M.D., postdoctoral echocardiography fellow at the Methodist DeBakey Heart and Vascular Center. "Our research found no link between its use and adverse events or any reason why it shouldn't be available to cardiologists whose patients would benefit from it."

For more information: www.debakeyheartcenter.com


Related Content

News | Radiology Business

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Interventional Radiology

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
Subscribe Now